The Board of Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, notes the recent rise in the Company’s share price and trading volumes and advises the market that it knows of no specific reason for such significant movements.
Further to its announcements of 27 May 2020 and 30 June 2020, the Company remains in the late stages of finalising a contract with the potential new large pharmaceutical client. While there is no guarantee that the contract will be entered into, the commercial terms have been agreed and the directors are confident it will be signed in the coming weeks. Should the contract be entered into, the project would take two of our technical staff around five months to complete. Further updates will be provided as and when appropriate in due course.
This announcement is released by Physiomics plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company’s obligations under Article 17 of MAR.